Next Article in Journal
Completion of Genetic Testing and Incidence of Pathogenic Germline Mutation among Patients with Early-Onset Colorectal Cancer: A Single Institution Analysis
Next Article in Special Issue
A Comprehensive Analysis of Tn and STn Antigen Expression in Esophageal Adenocarcinoma
Previous Article in Journal
Reproductive Results in Cancer Survivors after Fertility Sparing Management: The Need for the Standardization of Definitions
Previous Article in Special Issue
Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 14
10.3390/cancers15143571
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

N-Glycomic Profiling of Microsatellite Unstable Colorectal Cancer

by
Iiris Ukkola
1,2,
Pirjo Nummela
1,2,
Annamari Heiskanen
3,
Matilda Holm
1,2,4,5,†,‡,
Sadia Zafar
1,2,
Mia Kero
1,
Caj Haglund
4,5,
Tero Satomaa
3,
Soili Kytölä
6 and
Ari Ristimäki
1,2,*
1
HUSLAB, Department of Pathology, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, 00029 Helsinki, Finland
2
Applied Tumor Genomics Research Program, Research Programs Unit, Helsinki University Hospital and University of Helsinki, 00014 Helsinki, Finland
3
Glykos Finland Co., Ltd., 00790 Helsinki, Finland
4
Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland
5
Department of Surgery, Helsinki University Hospital and University of Helsinki, 00029 Helsinki, Finland
6
HUSLAB, Department of Genetics, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, 00029 Helsinki, Finland
*
Author to whom correspondence should be addressed.
†
Current address: Science for Life Laboratory, Department of Protein Science, KTH Royal Institute of Technology, 171 21 Solna, Sweden.
‡
Current address: Department of Biosciences and Nutrition, Karolinska Institutet, 141 83 Huddinge, Sweden.
Cancers 2023, 15(14), 3571; https://doi.org/10.3390/cancers15143571
Submission received: 12 June 2023 / Revised: 6 July 2023 / Accepted: 8 July 2023 / Published: 11 July 2023
(This article belongs to the Special Issue Glycosylation in Cancer—Biomarkers and Targeted Therapies)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

All human cells possess a complex glycan coating, and alterations in cell surface glycans play a role in cancer progression and immune suppression. Colorectal cancer is a heterogenous disease that can be classified into several molecular subtypes, with major variances in prognosis and therapy responses. Two important molecular markers in this regard are microsatellite instability and BRAF gene mutation, which have been largely ignored in previous glycomics studies. We analyzed the N-glycan profiles of local and advanced colorectal cancers consisting of different molecular subtypes to identify possible explanations for their differing behaviors. Our results show that the studied molecular subgroups of colorectal cancer exhibit characteristic glycan profiles, which may explain their tumorigenic properties.

Abstract

Aberrant glycosylation affects cancer progression and immune evasion. Approximately 15% of colorectal cancers (CRCs) demonstrate microsatellite instability (MSI) and display major differences in outcomes and therapeutic responses, as compared to corresponding microsatellite stable (MSS) tumors. We compared the N-glycan profiles of stage II and IV MSI CRC tumors, further subdivided into BRAFV600E wild-type and mutated subgroups (n = 10 in each subgroup), with each other and with those of paired non-neoplastic mucosal samples using mass spectrometry. Further, the N-glycans of BRAFV600E wild-type stage II MSI tumors were compared to corresponding MSS tumors (n = 9). Multiple differences in N-glycan profiles were identified between the MSI CRCs and control tissues, as well as between the stage II MSI and MSS samples. The MSI CRC tumors showed a lower relative abundance of high-mannose N-glycans than did the control tissues or the MSS CRCs. Among MSI CRC subgroups, acidic N-glycans showed tumor stage and BRAF mutation status-dependent variation. Specifically, the large, sulfated/phosphorylated, and putative terminal N-acetylhexosamine-containing acidic N-glycans differed between the MSI CRC subgroups, showing opposite changes in stages II and IV, when comparing BRAF mutated and wild-type tumors. Our results show that molecular subgroups of CRC exhibit characteristic glycan profiles that may explain certain carcinogenic properties of MSI tumors.

1. Introduction

Colorectal cancer (CRC) is a heterogenous disease that can be stratified by genomic and gene expression profiles into several distinct molecular subtypes, with major differences in prognosis and therapeutic response. Approximately 15% of CRCs arise from a microsatellite instability (MSI) pathway caused by a deficient mismatch repair (dMMR) system, leading to hypermutation and increased cancer susceptibility. The MMR system can be compromised by epigenetic changes, usually by acquired MLH1 promoter hypermethylation, or by genetic inactivation of MLH1, MSH2, MSH6, or PMS2 genes characteristic of Lynch syndrome (LS) [1,2]. Among all CRC tumors, stage II–III MSI CRCs have a better prognosis than corresponding microsatellite stable (MSS) tumors, whereas stage IV MSI CRCs exhibit a worse prognosis than corresponding MSS CRCs [1,2]. Further, BRAFV600E mutation has been associated with aggressive behavior in MSS tumors, but not in MSI tumors, suggesting that the MSI phenotype may override the negative prognostic potential of BRAFV600E mutation [3,4,5,6]. Immuno-oncological treatments with immune checkpoint inhibitors have shown excellent responses in advanced dMMR/MSI CRC patients [7,8] but only limited responses when treating MSS CRC patients [9,10]. Despite the clinical success, nearly half of metastatic dMMR/MSI CRCs fail to respond to immunotherapy [11,12]. The molecular mechanisms behind these differing responses are unclear.
All human cells have a complex glycan coating (the glycocalyx), which is involved in many essential cellular functions, such as cell signaling, adhesion, differentiation, and proliferation [13,14]. Altered glycosylation, most often increased sialylation, fucosylation, and branching of N-linked glycans, has been observed in many types of cancer cells [13,14]. Aberrantly expressed glycans can modulate essential events of cancer development and progression, including angiogenesis, invasion, and metastasis [13,14,15]. Further, the surface glycans of cancer cells play a role in the evasion of the immune response [16]. Glycan alterations may thus provide valuable novel molecular targets for cancer diagnostics and treatment.
N-glycan profiles of CRC tissues have previously been compared primarily with those of non-neoplastic colon tissues, and different stages of CRC have been compared, without considering the MSI status. Increased glycosylation features in CRC include pauci-mannosidic, β1,6-branched, sulfated and sialylated N-glycans, especially α2,6-sialylated glycans, as well as glycans containing sialylated Lewis type epitopes [17,18]. In turn, the decreased features include structures with a bisecting N-acetylglucosamine [17,18]. In our previous study, we also demonstrated differences in the levels of sialylated and sulfated glycans between stage II and III right-sided CRC samples, with stage III tumors showing predominantly sulfated and stage II exhibiting mainly sialylated N-glycans [19]. Also, a study by Kaprio et al. showed pauci-mannose and small high-mannose N-glycan structures, as well as sialylated structures, to be relatively more abundant in rectal carcinomas than in adenomas [20].
The aim of this study was to analyze the N-glycan profiles of MSI CRC tumors to identify possible reasons for their differing behaviors. We studied the neutral and acidic N-linked glycan profiles of MSI CRC samples (n = 40) and pools of paired non-neoplastic colon controls (n = 4) using MALDI-TOF mass spectrometry. The MSI CRC samples were further divided into subgroups according to the stage (II or IV) and BRAFV600E mutation status (wt or mut) (n = 10 in each group). In addition, the N-glycan profiles of stage II BRAFwt MSI tumors were compared to those of stage II BRAFV600E wt MSS tumors (n = 9).

2. Materials and Methods

2.1. Tissue Samples

Representative tissue samples from 40 MSI CRC patients were selected for the analysis. Of these patients, 38 had undergone surgical resection at Helsinki University Hospital (HUH) between 2018 and 2019, and the samples had been routinely screened for the MMR proteins MLH1, MSH2, MSH6, and PMS2 using immunohistochemistry (IHC). The selected samples showed loss of MLH1 expression (and concomitant loss of PMS2) and had also been routinely screened by BRAFV600E IHC in a real-life diagnostic setting. In addition, two MSI stage IV CRC samples from patients receiving surgery at HUH between 2014 and 2015 were included in the study. These samples were also determined to be dMLH1 by IHC, and the BRAFV600E status had been analyzed by next generation sequencing (NGS). The primary selection of MSI (dMLH1) CRC samples was performed based on tumor stage (II or IV) and BRAFV600E mutation status (mut or wt). Secondary selection was conducted based on patient age, sex, and tumor location (right or left side) to achieve similar study groups. For each of the MSI CRC subgroups (BRAFwt stage II, BRAFwt stage IV, BRAFmut stage II, and BRAFmut stage IV), 10 samples were selected. In addition to the BRAFV600E IHC, the BRAF mutation status was confirmed by NGS in stage IV CRC samples and by droplet digital polymerase chain reaction (ddPCR) in stage II samples. Further, a pool of paired non-neoplastic colon samples from each MSI CRC patient set (four pools, n = 10 in each pool) was included in the glycomic profiling to serve as control tissues. For MSS reference sample set, we used our previously analyzed stage II MSS CRC samples [19]. From this published cohort, we selected only the stage II pMMR/MSS and BRAFwt cases (n = 9) by using MMR and BRAFV600E IHC. These MSS stage II CRC patients had been operated on at HUH between 2001 and 2003.

2.2. BRAF Mutation Analysis

BRAFV600E mutation status was confirmed by NGS in stage IV MSI CRC samples and by ddPCR in stage II MSI CRC samples. NGS analysis was performed using an in-house cancer panel containing the BRAF exons 11–15 (in addition to the coding regions of PIK3CA, EGFR, KIT, KRAS, MET, NRAS, and PDGFRA), performed as previously described [21].
For the ddPCR analysis, targeted wild-type and BRAFV600E mutation probes were designed and prevalidated by Bio-Rad (www.biorad.com), and 2 μL (100 ng) of the extracted DNA from formalin-fixed paraffin-embedded (FFPE) tissue samples was used for each duplicate reaction. Droplet generation and reading were performed according to the manufacturer’s protocol using QX200 Droplet Generator and QX200 Droplet Reader (Bio-Rad, Hercules, CA, USA), respectively. The droplet generator first partitioned the samples for PCR amplification (22 μL into 20,000 droplets), and the droplets from each sample were then analyzed individually on the droplet reader. The data were processed using the QuantaSoft Analysis Pro Software (v.1.0; Bio-Rad).

2.3. N-Glycan Isolation

Representative areas of the carcinoma tissue, or areas containing the highest percentages of epithelial cells in the paired non-neoplastic colon tissues, were marked on HE slides, and macrodissection was used to cut 10 µm thick flakes from the FFPE tissue blocks with a Leica SM2000R microtome (Leica Microsystems GmbH, Wetzlar, Germany). After the last flake was obtained, a new HE slide was stained to verify the representativeness of the flakes. The tissue flakes were deparaffinized with xylene and rehydrated with a descending ethanol series, according to standard procedures, and N-linked glycans were liberated by N-glycosidase F (PNGase F) digestion (Glyko; ProZyme Inc., Hayward, CA, USA) overnight at 37 °C. N-glycan purification was then conducted, as previously described [20], using the 96-well format. Briefly, the extracted glycans were passed through C18 silica in water and then absorbed into graphitized carbon material. The carbon wells were washed with water, and neutral N-linked glycans were eluted using 25% acetonitrile and acidic N-linked glycans with 0.05% trifluoroacetic acid in 25% acetonitrile in water. The acidic N-glycans were further purified with hydrophilic interaction solid-phase extraction. Both glycan fractions were then additionally passed through strong cation-exchange resin and C18 silica resin in water.

2.4. Mass Spectrometry

Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) was performed using a Bruker Ultraflex III TOF/TOF instrument (Bruker Daltonics Inc., Bremen, Germany), as previously described [20]. Neutral N-linked glycans were detected in positive ion reflector mode as (M+Na)+ ions, and acidic N-linked glycans were identified in negative ion reflector mode as (M-H)− ions. Representative unprocessed MALDI TOF mass spectra of neutral and acidic N-linked glycans are shown in Supplementary Figure S1. The relative molar abundances of both neutral and acidic N-glycan components were assigned based on their relative signal intensities in the mass spectra when analyzed separately as neutral and acidic glycan fractions. The unprocessed mass spectrometric data were first transformed into the present glycan profiles by removing the effects of isotopic pattern overlapping, alkali-metal adduct signals, water elimination products from reducing oligosaccharides, and other interfering mass spectrometric signals not arising from the original glycans in the sample, as previously described [22,23]. The resultant glycan signals in the glycan profiles were then normalized to 100% to allow for the relative quantitative comparison between the samples. Normalized values were further assigned to structural/biosynthetic glycan classes based on their proposed monosaccharide composition, as previously described [22,23]. The validation of proposed monosaccharide compositions identified by this method in colon and lung carcinoma specimens has been presented in the previous study by Satomaa et al. [22]. Further, proposed monosaccharide compositions and identified N-glycan features of CRC tumor specimens have also been validated in a detailed study by Balog et al. [17]. All the glycan signal intensities and relative abundances of both glycans and glycan classes identified in this study are listed in Supplementary Tables S1 and S2. The mass spectrometry proteomics data from the previously analyzed stage II BRAFV600E wt MSS CRC samples have been deposited in the ProteomeXchange Consortium via the PRIDE [24,25] partner repository, with the dataset identifier PXD018673 (samples AH25-31-21-1/2, AH25-31-8-1/2, AH25-31-12-1/2, AH25-31-20-1/2, AH25-31-4-1/2, AH25-31-13-1/2, AH25-31-9-1/2, AH25-31-5-1/2, and AH25-31-37-1/2).

2.5. Analysis of N-Linked Glycan Profiles

In seven different study group settings, statistical analysis of the N-linked glycan data was performed between non-neoplastic colon samples (four pools of paired control samples), subgroups of MSI CRC samples, according to the tumor stage and BRAF mutation status, and stage II BRAFV600E wt MSI CRCs were compared to stage II BRAFV600E wt MSS tumors (Table 1). Both the relative abundances of proposed monosaccharide compositions and glycan classes were analyzed separately within these study groups. For statistical analyses, the nonparametric Kruskal–Wallis test was first used to verify the equality of the mean ranks of the groups, and the Mann–Whitney U test, along with the Benjamini–Hochberg false discovery rate (FDR) correction method [26], was then used for pairwise comparisons of the groups. RStudio (version 2022.07.2-576; Posit Software, Boston, MA, USA) was used for statistical analyses, and p-value < 0.05 was considered statistically significant. The results are shown as mean relative abundance ± standard error of mean (SEM) for the separately calculated neutral and acidic N-glycan compositions and structural glycan classes.

2.6. Immunohistochemistry

For IHC analyses, 4 μm sections cut from the FFPE tissue blocks were used. The MMR and BRAFV600E IHC were performed, as previously described [27,28].

3. Results

3.1. Clinicopathological Characteristics of the CRC Cases

Our study consisted of 40 MSI CRC samples, which were subdivided into four different subgroups (n = 10 in each group) according to tumor stage (II or IV) and BRAFV600E mutation status (wt or mut) (Table 1). Of these patients, the median age was 73 (range 51–89), 70% were females, and the tumors were mainly localized to the right colon (80–100%), which are typical characteristics of MSI CRC patients (Table 2). MSI stage II tumors were mainly pT3 (70–80%) and low-grade (60%). MSI stage IV BRAFwt CRCs were more often high-grade (60% vs. 30%) and pT4 (60% vs. 30%), more often displaying peritoneal metastasis (M1c, 40% vs. 10%) when compared to MSI stage IV BRAFmut CRCs (Table 2). Stage IV MSI CRCs presented mainly synchronous metastases (16/20, 80%), and four cases were diagnosed with metachronous metastases at less than 6 months (2–5 months) follow-up. In the MSS stage II BRAFwt subgroup (n = 9), a slight predominance of male sex (56%) and left-sided localization (56%) was observed, and the median age of the patients was 59 (range 52–77). Similar to the results for MSI stage II CRCs, the MSS tumors were mainly pT3 (89%) and low-grade (78%) (Table 2).

3.2. N-Linked Glycan Profiles

3.2.1. N-Glycan Profiles of MSI CRC Samples and Paired Non-Neoplastic Control Samples

The major glycan types and structural features reported in this study are shown in Figure 1. Most of the differences between paired non-neoplastic colon samples (four pools) and MSI CRC samples (n = 40) were detected in the neutral N-glycan profiles. Relative abundances of pauci-mannose, biantennary-size complex-type, monoantennary hybrid-type, fucosylated pauci-mannose (especially H2N2F1), and fucosylated hybrid-type glycans were significantly higher in the MSI tumor samples than in the controls (Table 3). Respective comparisons of proposed monosaccharide compositions are shown in Supplementary Table S3. In contrast, the relative abundances of five N-acetylhexosamines (HexNAc = N) containing glycans (i.e., complex-type), high-mannose type glycans (e.g., compositions H6N2, H9N2, and H10N2), and a putative terminal HexNAc (N > H > 1) containing glycans were significantly lower in the MSI tumor samples than in the controls (Table 3 and Supplementary Table S3). In addition, the complex-type glycan structures with fucose and putative terminal HexNAc, e.g., H3N5F1 and H4N5F1, as well as the putative bisecting (N = H ≥ 5) N-acetylglucosamine structures H5N5F1 and H5N5F2, showed decreased abundances in MSI CRC as compared to the controls (Supplementary Table S3). In the acidic N-glycan profiles, only fucosylated complex-type glycans showed significant change, i.e., a decrease in MSI CRCs as compared to the controls (Table 3). Further, several multifucosylated and putatively sulfated N-glycan structures (e.g., H5N4F3P1, H4N5F3P1, H5N5F2P1, H5N5F3P1, and H6N6F3P1) were less abundant in the MSI tumor samples (Supplementary Table S3).

3.2.2. N-Glycan Profiles between Stage II MSI and MSS Samples

The neutral N-glycan profiles of MSI BRAFwt stage II CRC samples (n = 10) were clearly different from those of our MSS BRAFwt stage II samples (n = 9). The MSI stage II CRC samples showed distinctively higher relative abundances of several neutral N-glycan classes, including complex-type glycans (4 HexNAc and 5 HexNAc), biantennary-size complex-type glycans, monoantennary hybrid-type glycans, and fucosylated glycans (particularly fucosylated pauci-mannose type glycans, e.g., H2N2F1), than did the MSS samples (Table 4). Further, the putative terminal HexNAc containing glycan H3N4F1 and fucosylated complex-type glycans H4N4F1, H5N4F1, H5N5F1, and H6N5F1 were more abundant in the MSI than in MSS samples (Supplementary Table S4). On the contrary, the MSI Stage II CRC samples showed lower abundances of oligomannose structures (N2 = 2 HexNAc, e.g., high-mannose type H5N2, H6N2, H7N2, and H8N2, and pauci-mannose type H2N2, H3N2, and H4N2), hybrid-type (3 HexNAc), and high-mannose type structures, as well as putative terminal HexNAc containing complex-type glycans, than did the MSS Stage II CRC (Table 4 and Supplementary Table S4).
Acidic N-glycan profiles of the MSI BRAFwt stage II CRC samples vs. the corresponding MSS cases showed a higher number of significantly different glycan classes than the neutral N-glycan profiles. Four HexNAc containing (N4) and biantennary-size complex-type N-glycans were relatively more abundant in the MSI stage II CRC samples than in the MSS stage II (Table 5), as well as the sialylated and multisialylated complex-type glycans S1H5N4F1, S1H5N4F2, S2H5N4, S2H5N4F1, S3H6N5, and S3H6N5F1 (Supplementary Table S5). Among the less abundant N-glycan classes in the MSI stage II as compared to MSS stage II samples were hybrid-type glycans (3 HexNAc) and large N-glycans (≥5 HexNAc), as well as fucosylated and complex fucosylated glycans (both features particularly noted in complex-type glycans, as well as complex fucosylation noted in the hybrid-type), putative terminal HexNAc structures (especially in the complex-type and bisecting size complex-type glycans), and acid ester-modified (sulfated/phosphorylated) hybrid-type N-glycans (Table 5).

3.2.3. N-Glycan Profiles between BRAFwt and BRAFmut Stage II MSI Samples

When MSI stage II BRAFwt cases were compared to corresponding BRAFmut samples, only minor differences were observed in neutral N-glycan profiles, the fucosylated hybrid-type structures H2N3F1 and H3N3F1 being slightly increased in the BRAFmut samples (Supplementary Table S6). The acidic N-glycan profiles in turn displayed more differences, with the BRAFmut samples showing increased relative abundances of 4 HexNAc and biantennary-size complex type glycans, as well as sialylated complex-type glycans (especially S2H5N4) (Table 6 and Supplementary Table S7). Among the less abundant glycan classes in the BRAFmut stage II MSI samples were large N-glycans (≥5 HexNAc) and putative terminal HexNAc containing glycans, especially terminal HexNAc in complex-type and bisecting size complex-type glycans. (Table 6). Interestingly, no sulfated/phosphorylated N-glycans were identified in any of the BRAFmut stage II MSI CRC samples, and all detected acidic N-glycans were sialylated (Table 6).

3.2.4. N-Glycan Profiles between Stage II and Stage IV MSI Samples

Only minor changes were observed in the neutral or acidic N-glycan profiles between all MSI stage II samples and MSI stage IV samples (n = 20 in both groups). In the neutral profiles, slight relative increases in hybrid-type glycans and fucosylated high-mannose type glycans, as well as the composition H3N4 (complex-type with putative terminal HexNAc), were detected in stage IV samples, whereas the composition H7N6F1 (fucosylated complex-type) showed a slight decrease in stage IV samples (Table 7 and Supplementary Table S6). When acidic N-glycan classes were compared, only biantennary-size complex-type glycans showed a relative decrease in stage IV samples (Table 6). Of the separate glycan structures, the sialylated S1H4N4F1 and the multisialylated S2H6N5 and S2H7N6F1 structures showed slightly higher relative abundance in the MSI stage IV samples than in the stage II samples (Supplementary Table S7).

3.2.5. N-Glycan Profiles between Stage II and Stage IV in BRAFwt CRC

When the MSI BRAFwt II samples were compared to corresponding stage IV samples, only minor relative changes were observed in the neutral or acidic N-glycan profiles. In the neutral N-glycan profiles, only a few separate monosaccharide compositions showed significant differences, e.g., fucosylated hybrid-type structures H2N3F1 and H3N3F1 were more abundant in BRAFwt stage IV than in the stage II samples (Supplementary Table S6). In the acidic N-glycan profiles, a higher abundance of biantennary-size complex type glycans, but a clearly lower abundance of large-N-glycans (especially 5 HexNAc and 7 HexNAc or larger) was seen in the stage IV as compared to stage II samples (Table 6).

3.2.6. N-Glycan Profiles between Stage II and Stage IV in BRAFmut CRC

Between the MSI BRAFmut stage II and IV samples, neutral N-glycan profiles similarly showed only minor relative changes, with monoantennary hybrid-type glycans and the fucosylated hybrid-type composition H2N3F1 being less abundant in BRAFmut stage IV than in stage II samples (Table 7 and Supplementary Table S6). More versatile relative differences were detected in the acidic N-glycan profiles of these MSI subgroups. In the BRAFmut stage IV samples, large N-glycans, putative terminal HexNAc containing glycans (especially in complex-type and bisecting sized complex-type glycans), and sulfated/phosphorylated complex-type glycans were significantly more abundant than in stage II samples, whereas 4 HexNAc, biantennary-size complex-type and sialylated complex-type glycans (especially S2H5N4) were relatively less abundant in BRAFmut stage IV than in stage II (Table 6 and Supplementary Table S7). Here it should be noted that the BRAFmut stage II MSI samples completely lacked the sulfated/phosphorylated N-glycans.

3.2.7. N-Glycan Profiles between BRAFwt and BRAFmut Stage IV MSI Samples

Finally, when comparing the neutral N-glycan profiles between MSI stage IV BRAFwt and BRAFmut samples, only fucosylated pauci-mannose glycans and the composition H2N3F1 (fucosylated hybrid-type glycan) were significantly different, being less abundant in BRAFmut stage IV samples (Table 7 and Supplementary Table S6). The acidic profiles differed more significantly, and in direct contrast to the differences between MSI Stage II BRAFwt and BRAFmut samples, the MSI stage IV BRAFwt and BRAFmut samples showed differences in the same glycan classes, but in the opposite direction (Figure 2). The stage IV BRAFmut samples thus showed higher relative abundances of large N-glycans and putative terminal HexNAc structures (especially in complex-type and bisecting-size complex-type glycans), as well as sulfated/phosphorylated complex-type glycans, but fewer 4 HexNAc and biantennary-size complex-type glycans than did the BRAFwt stage IV samples (Table 6). The sialylated glycans were an exception, as those classes did not show significant differences between the stage IV subgroups. Of the monosaccharide compositions, the sialylated complex-type structures S1H5N5F1 and S1H6N5 showed a slight increase in relative abundance, and S1H4N4F1 showed a decrease in stage IV BRAFmut when compared to the corresponding BRAFwt samples (Supplementary Table S7).

4. Discussion

In this study, we investigated the N-linked glycan profiles of MSI CRC tissue specimens subdivided into subgroups according to stage (II or IV) and BRAFV600E mutation status (wt or mut) using MALDI-TOF mass spectrometry. Further, we compared these glycan profiles to those of both paired non-neoplastic colon tissue samples and MSS CRC specimens. We found multiple differences between the MSI CRC samples and the control samples, and between the MSI stage II and MSS stage II CRC samples. When the MSI CRC subgroups were compared to each other, only minor differences were found in neutral N-glycan profiles, whereas a clear association between tumor stage and BRAF mutation status was observed in the acidic N-glycan profiles. Most interestingly, no acid ester-modified (sulfated/phosphorylated) N-glycans were identified in any of the stage II MSI tumors with the BRAFV600E mutation.
In line with previous glycomic profiling reports of CRC tissues [17,18,19], MSI CRC tumors showed a higher relative abundance of neutral pauci-mannose N-glycans, especially the fucosylated glycan H2N2F1, and a decreased relative abundances of the putative terminal HexNAc (e.g., H3N5, H3N5F1, and H4N5F1) containing glycans, as well as the bisecting-size structure H5N5F1, as compared to the control tissues. In contrast to previous CRC reports, which have not specifically taken into account the MSI/MSS status [29,30,31,32], MSI tumors exhibited a lower relative abundance of high-mannose type N-glycans than did the non-neoplastic control tissues. Boyaval et al. [32] demonstrated even higher levels of high-mannose type N-glycans in the dysplastic regions of pre-cursor lesions than in early-stage CRC. Notably, in a recent study, the overexpression of high-mannose N-glycans was demonstrated, specifically in MSS CRC tumor tissue [33]. The acidic N-glycan profiles of MSI tumors were relatively simple, and, in contrast to the results of previous reports, MSI tumors showed a decreased relative abundances of some sulfated/phosphorylated and complex fucosylated structures, e.g., H5N4F3P1 and H5N6F4P1, as compared to the control tissues [17,19]. Fucosylated neutral pauci-mannose and hybrid-type glycans were detected to increase, while fucosylated acidic complex-type glycans were observed to decrease, in the MSI CRC samples compared to the non-neoplastic controls. Similarly, a higher abundance of fucosylated neutral N-glycans has been reported by Holm et al. [19] and a lower abundance of fucosylated complex-type N-glycans by Boyaval et al. [31] in CRC compared to the results for adjacent normal colon epithelium. Further, we did not find any statistically significant differences in the relative abundances of sialylated N-glycans between the MSI CRC samples and the control tissues, whereas previous reports have reported increased levels of sialylation in CRC [17,29,31,34], and increased sialylation has also been attributed to metastatic potential and therapeutic resistance in CRC [35,36].
When comparing BRAFwt stage II MSI and MSS tumors, multiple significant differences were observed, both in the neutral and acidic N-glycan profiles. The MSI tumors showed distinctively higher relative abundances of neutral complex-type and monoantennary hybrid-type glycans, as well as fucosylation, especially in pauci-mannose glycans. On the contrary, a clearly lower abundance of 2 HexNAc and high-mannose type glycans, as well as putative terminal HexNAc complex-type structures, was observed in the MSI than in MSS stage II tumors. In the acidic N-glycan profiles, MSI stage II BRAFwt tumors showed increased relative abundances of biantennary-size complex-type N-glycans and 4 HexNAc complex-type glycans than did the corresponding MSS samples. However, sulfated/phosphorylated hybrid-type glycans, large glycans, and putative terminal HexNAc containing complex-type glycans, as well as fucosylated, especially fucosylated/complex fucosylated complex-type glycans, were significantly less abundant in the MSI stage II BRAFwt tumors. These neutral and acidic N-glycan types, with differing abundances in MSI stage II CRC compared to corresponding MSS tumors, may be linked to the MSI pathway of CRC. To our knowledge, this is the first study to report significant N-glycosylation differences between MSI and MSS CRC tissue samples.
Between MSI CRC subgroups, only minor differences were found in neutral N-glycan profiles, and the major differences were observed in the acidic N-glycan profiles. Most interestingly, no sulfated/phosphorylated N-glycans were identified in any of the stage II MSI tumors containing the BRAFV600E mutation. Between all MSI stage II and stage IV CRC, only acidic biantennary-size complex-type glycans showed a clear decrease in the stage IV samples. When comparing MSI BRAFwt stage II and IV CRC samples to each other, biantennary-size complex type glycans were more abundant, and larger N-glycans were less abundant in stage IV samples. Between the BRAFmut stage II and stage IV samples, large N-glycans, putative terminal HexNAc containing, and sulfated/phosphorylated complex-type glycans were significantly more abundant, and 4 HexNAc, biantennary-size complex-type and sialylated complex-type glycans were less abundant in the stage BRAFmut IV samples. The most interesting differences were observed when comparing the MSI BRAFwt and BRAFmut samples within stages. In these comparisons, the same glycan classes differed between the BRAFwt and BRAFmut samples, but the direction of the change was totally opposite in stage II versus stage IV. In the stage II BRAFmut samples, sulfated, large, and putative terminal HexNAc containing acidic N-glycans were decreased when compared to the corresponding BRAFwt samples, whereas in stage IV, these same N-glycan features were increased in the BRAFmut as compared to the BRAFwt samples. On the other hand, increased levels of biantennary-size complex-type glycans, especially 4 HexNAc glycans, were observed in the stage II BRAFmut samples as compared to the corresponding BRAFwt samples, whereas in the stage IV samples, these same glycan classes were decreased in the BRAFmut relative to the BRAFwt samples. The BRAFV600E mutation is known to have a negative prognostic value in MSS CRC, while MSI has been suggested to override this negative effect [3,4,6]. Some studies have reported that the BRAF mutation could be a positive prognostic marker in early stage MSI CRC [37], but a negative prognostic factor in advanced MSI CRC [38,39]. The oppositely behaving acidic N-glycan types, especially large, sulfated/phosphorylated, and putative terminal HexNAc containing glycans, showed a clear dependence on tumor stage and BRAF mutation status and may thus be associated with MSI CRC progression according to BRAF mutation.
Large N-glycans commonly contain β1,6-branching, and an increase in β1,6-branched N-linked glycans has been related to malignant transformation and metastatic potential in many cancers, including CRC [13,40,41,42]. Importantly, the modification of epithelial cadherin (E-cadherin) with branched glycans is known to interfere with cellular adhesion and promote tumor invasiveness and metastasis [13,43]. Also, Kaprio et al. [20] reported a significantly higher abundance of acidic N5 glycans in tissue from stage III CRC compared to stage I–II CRC samples. The enzyme catalyzing β1,6-branching of N-glycans is N-acetylglucosaminyltransferase V (GnT-V), encoded by the MGAT5 gene. MGAT5 expression is regulated by the RAS–RAF–MAPK pathway, and mutations of this oncogenic pathway are known to upregulate GnT-V expression and concomitant β1,6-branching [13]. This is in line with our findings showing increased levels of large (N ≥ 5) acidic N-glycans in BRAFmut stage IV as compared to those of the corresponding BRAFwt tumors but contradicts with the findings that BRAFmut stage II tumors show lower levels of these glycans as compared to those of the corresponding BRAFwt samples. Also, in our study, BRAFwt MSI stage II samples showed a lower relative abundance of large acidic N-glycans than did the BRAFwt stage II MSS tumors, thus potentially explaining, to some degree, the better prognosis of early stage MSI CRC as compared to corresponding MSS tumors.
Sulfated glycans have been shown to play an important role in many cell surface-related functions, such as cellular adhesion and selectin–ligand interactions [44]. Higher levels of glycan-sulfotransferase activities have been demonstrated in poorly differentiated gastric carcinomas than in moderately differentiated tumors, thus being associated with gastric tumorigenesis [45]. Moreover, sulfated Lewis X determinants form a predominant structural glycan motif in the xenograft tumor mucin of LS174T-HM7 cells, a highly metastatic subline of the LS174T human CRC cell line [46]. Sulfated glycans are preferably bound by galectin-1 and galectin-2 [47], and the upregulation of galectin-1 has been related to malignant progression in CRC [48,49]. In our study, sulfated/phosphorylated complex-type glycans were increased with the tumor stage in the MSI BRAFmut, but not in the MSI BRAFwt, samples. Strikingly, sulfated/phosphorylated N-glycans were not found in any of the stage II MSI BRAFmut tumors, whereas MSI BRAFwt stage II tumors displayed these glycans. Further, MSI stage II BRAFwt tumors showed a lower relative abundance of sulfated/phosphorylated hybrid-type glycans when compared to the corresponding MSS samples.
Putative terminal HexNAc-containing N-glycans (N > H > 1) have previously been identified in various CRC cell lines, and an increased abundance of terminal HexNAc residues has further been correlated with caudal-related homeobox protein 1 (CDX1) expressing CRC cells [50,51]. CDX1 is a transcription factor regulating the normal development and differentiation of the intestinal epithelium and is associated with tumor suppressing potential in the colon [52]. More specifically, increased terminal N-acetylglucosamine (GlcNAc) has been identified in various carcinomas [22]. N-glycans containing bisecting GlcNAc have been more significantly attributed to the suppression of tumor progression and metastasis through the regulation of cell surface glycoproteins, such as stabilizing the E-cadherin mediated cell–cell adhesion [13,43]. N-glycans containing bisecting GlcNAc have also been reported to decrease in CRC tissue samples with more advanced tumor stages [30,34]. In contrast, in our study, stage IV BRAFmut tumors showed a higher relative abundance of acidic putative terminal HexNAc, especially in bisecting-size, containing complex-type glycans when compared to corresponding stage II samples. However, a higher expression of bisecting N-glycans in a metastatic MSI CRC cell line (LIM1215) as compared with two non-metastatic MSI CRC cell lines (LIM1899 and LIM2405) has also been controversially demonstrated by Sethi et al. [53]. Further, the acidic putative terminal HexNAc and terminal HexNac in bisecting-size complex-type glycans showed a significantly lower relative abundance in MSI stage II than in corresponding MSS samples.
A limitation of our study is that the mass spectrometric analyses were conducted using flakes from FFPE tissue blocks. Thus, it is not possible to specify from which cell type (e.g., cancer or stromal cells) the detached glycans originated. The tumor stroma is composed of various non-neoplastic cells, e.g., immune cells, fibroblasts, and endothelial cells, as well as the extracellular matrix that forms a tumor microenvironment promoting cancer growth and spreading [54]. Moreover, the cancer related N-glycan signature has been demonstrated to spread into the stroma at the invasive front of the tumor [31]. We, however, used macrodissection to exclude the distant stroma and to achieve the highest percentage of epithelial cells in the carcinoma and non-neoplastic tissues. The analyzed tissues (tumor epithelium percentages 30–80%), however, included varying amounts of tumor mucin, intra-tumor stroma, and surrounding interface stroma, which may contribute to the heterogeneity of the N-glycan signatures found in this study. An additional limitation of this study is that we used pools of paired non-neoplastic colon samples from each MSI CRC patient set, instead of individual paired non-neoplastic control samples. However, the main aim of this study was to compare the N-glycan profiles between MSI and MSS CRC samples, specifically between different MSI CRC subgroups.

5. Conclusions

Our study identified multiple differences in N-glycan profiles between the MSI tumors and the control tissues, the stage II MSI and MSS CRC samples, and within different MSI subgroups. Most importantly, we demonstrated that molecular subgroups of MSI CRCs exhibit distinct glycan profiles that may explain certain carcinogenic characteristics of these CRC subtypes. After further characterization and validation, these N-glycan features may provide new biomarkers to refine the prognosis of MSI CRC tumors. Further, immunotherapy strategies targeting cancer-associated glycan features may be potential therapeutic agents [55]. Here, the identification of the carrier glycoproteins could also open new possibilities for specific diagnostics and targeted therapies by exploiting glycan-protein epitopes.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers15143571/s1, Figure S1: Representative unprocessed MALDI-TOF mass spectra of (A) neutral and (B) acidic N-linked glycans isolated from a tumor tissue sample from a patient with stage II MSI BRAFV600E wild-type colon cancer. Note the different scales on the y-axes; Table S1: MS data of acidic N-glycans; Table S2: MS data of neutral N-glycans; Table S3: Significantly different neutral and acidic monosaccharide compositions between controls (n = 4 pools) and MSI CRC samples (n = 40); Table S4: Significantly different neutral monosaccharide compositions between MSS BRAFwt stage II and MSI BRAFwt stage II samples; Table S5: Significantly different acidic monosaccharide compositions between MSS BRAFwt stage II and MSI BRAFwt stage II samples; Supplementary Table S6: Significantly different neutral monosaccharide compositions between MSI subgroups; Table S7: Significantly different acidic monosaccharide compositions between MSI subgroups.

Author Contributions

The study conception was formulated by I.U., P.N. and A.R. Data collection and material preparation were performed by I.U., P.N., M.K., M.H., S.K., C.H. and A.R. The data curation was contributed by A.H. and T.S., and the formal analysis was performed by I.U., A.H., T.S. and S.Z. All authors had a role in the detailed analysis of the data. Visualization of the manuscript was performed by I.U., P.N. and T.S. The original draft of the manuscript was written by I.U., P.N. and A.R., and all authors commented on previous versions of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Cancer Foundation Finland; Finska Läkaresällskapet; Helsinki University Central Hospital Research Funds; Medicinska Understödsföreningen Liv & Hälsa; Orion Research Foundation sr [I.U.]; the Ida Montin Foundation [I.U.]; the Sigrid Jusélius Foundation [M.H., C.H., A.R.]; and the University of Helsinki. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Helsinki University Central Hospital (DNRO 239/13/03/02/2011, 9 November 2011). All methods were performed in accordance with the relevant guidelines and regulations. Data were anonymized prior to use for the study.

Informed Consent Statement

Informed consent is not required by national regulations for research with de-identified samples and data.

Data Availability Statement

Data is contained within the article or Supplementary Materials.

Acknowledgments

The authors thank Merja Haukka for providing excellent technical assistance.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Gupta, R.; Sinha, S.; Paul, R.N. The impact of microsatellite stability status in colorectal cancer. Curr. Probl. Cancer 2018, 42, 548–559. [Google Scholar] [CrossRef] [PubMed]
  2. Diao, Z.; Han, Y.; Chen, Y.; Zhang, R.; Li, J. The clinical utility of microsatellite instability in colorectal cancer. Crit. Rev. Oncol. Hematol. 2021, 157, 103171. [Google Scholar] [CrossRef] [PubMed]
  3. Seppälä, T.T.; Bohm, J.; Friman, M.; Lahtinen, L.; Väyrynen, V.M.J.; Liipo, T.K.E.; Ristimäki, A.P.; Kairaluoma, M.V.J.; Kellokumpu, I.H.; Kuopio, T.; et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br. J. Cancer 2015, 112, 1966–1975. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Bläker, H.; Alwers, E.; Arnold, A.; Herpel, E.; Tagscherer, K.E.; Roth, W.; Jansen, L.; Walter, V.; Kloor, M.; Chang-Claude, J.; et al. The Association between Mutations in BRAF and Colorectal Cancer—Specific Survival Depends on Microsatellite Status and Tumor Stage. Clin. Gastroenterol. Hepatol. 2019, 17, 455–462.e6. [Google Scholar] [CrossRef] [Green Version]
  5. Fanelli, G.N.; Pozzo, C.A.D.; Depetris, I.; Schirripa, M.; Brignola, S.; Biason, P.; Balistreri, M.; Santo, L.D.; Lonardi, S.; Munari, G.; et al. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell Int. 2020, 20, 30. [Google Scholar] [CrossRef] [Green Version]
  6. Offermans, K.; Jenniskens, J.C.A.; Simons, C.C.J.M.; Samarska, I.; Fazzi, G.E.; van der Meer, J.R.M.; Smits, K.M.; Schouten, L.J.; Weijenberg, M.P.; Grabsch, H.I.; et al. Association between mutational subgroups, Warburg-subtypes, and survival in patients with colorectal cancer. Cancer Med. 2022, 12, 1137–1156. [Google Scholar] [CrossRef]
  7. Luchini, C.; Bibeau, F.; Ligtenberg, M.; Singh, N.; Nottegar, A.; Bosse, T.; Miller, R.; Riaz, N.; Douillard, J.-Y.; Andre, F.; et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Ann. Oncol. 2019, 30, 1232–1243. [Google Scholar] [CrossRef] [Green Version]
  8. Yoshino, T.; Pentheroudakis, G.; Mishima, S.; Overman, M.; Yeh, K.-H.; Baba, E.; Naito, Y.; Calvo, F.; Saxena, A.; Chen, L.-T.; et al. JSCO—ESMO—ASCO—JSMO—TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann. Oncol. 2020, 31, 861–872. [Google Scholar] [CrossRef]
  9. Golshani, G.; Zhang, Y. Advances in immunotherapy for colorectal cancer: A review. Ther. Adv. Gastroenterol. 2020, 13, 1756284820917527. [Google Scholar] [CrossRef]
  10. Carlsen, L.; Huntington, K.E.; El-Deiry, W.S. Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers. Cancers 2022, 14, 1028. [Google Scholar] [CrossRef]
  11. Ganesh, K.; Stadler, Z.K.; Cercek, A.; Mendelsohn, R.B.; Shia, J.; Segal, N.H.; Diaz, L.A., Jr. Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 361–375. [Google Scholar] [CrossRef] [PubMed]
  12. Sveen, A.; Kopetz, S.; Lothe, R.A. Biomarker-guided therapy for colorectal cancer: Strength in complexity. Nat. Rev. Clin. Oncol. 2019, 17, 11–32. [Google Scholar] [CrossRef]
  13. Pinho, S.S.; Reis, C.A. Glycosylation in cancer: Mechanisms and clinical implications. Nat. Rev. Cancer 2015, 15, 540–555. [Google Scholar] [CrossRef] [PubMed]
  14. Mereiter, S.; Balmaña, M.; Campos, D.; Gomes, J.; Reis, C.A. Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading? Cancer Cell 2019, 36, 6–16. [Google Scholar] [CrossRef]
  15. Marth, J.D.; Grewal, P.K. Mammalian glycosylation in immunity. Nat. Rev. Immunol. 2008, 8, 874–887. [Google Scholar] [CrossRef] [Green Version]
  16. Läubli, H.; Borsig, L. Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis. Front. Immunol. 2019, 10, 2120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Balog, C.I.A.; Stavenhagen, K.; Fung, W.L.J.; Koeleman, C.A.; McDonnell, L.A.; Verhoeven, A.; Mesker, W.E.; Tollenaar, R.A.E.M.; Deelder, A.M.; Wuhrer, M. N-glycosylation of Colorectal Cancer Tissues. Mol. Cell Proteom. 2012, 11, 571–585. [Google Scholar] [CrossRef] [Green Version]
  18. Sethi, M.K.; Fanayan, S. Mass Spectrometry-Based N-Glycomics of Colorectal Cancer. Int. J. Mol. Sci. 2015, 16, 29278–29304. [Google Scholar] [CrossRef] [Green Version]
  19. Holm, M.; Nummela, P.; Heiskanen, A.; Satomaa, T.; Kaprio, T.; Mustonen, H.K.; Ristimäki, A.; Haglund, C. N-glycomic profiling of colorectal cancer according to tumor stage and location. PLoS ONE 2020, 15, e0234989. [Google Scholar] [CrossRef]
  20. Kaprio, T.; Satomaa, T.; Heiskanen, A.; Hokke, C.H.; Deelder, A.M.; Mustonen, H.K.; Hagström, J.; Carpen, O.; Saarinen, J.; Haglund, C. N-glycomic Profiling as a Tool to Separate Rectal Adenomas from Carcinomas. Mol. Cell Proteom. 2015, 14, 277–288. [Google Scholar] [CrossRef] [Green Version]
  21. Holm, M.; Andersson, E.; Osterlund, E.; Ovissi, A.; Soveri, L.-M.; Anttonen, A.-K.; Kytölä, S.; Aittomäki, K.; Osterlund, P.; Ristimäki, A. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing. PLoS ONE 2020, 15, e0239819. [Google Scholar] [CrossRef]
  22. Satomaa, T.; Heiskanen, A.; Leonardsson, I.; Ångström, J.; Olonen, A.; Blomqvist, M.; Salovuori, N.; Haglund, C.; Teneberg, S.; Natunen, J.; et al. Analysis of the Human Cancer Glycome Identifies a Novel Group of Tumor-Associated N-Acetylglucosamine Glycan Antigens. Cancer Res. 2009, 69, 5811–5819. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Satomaa, T.; Heiskanen, A.; Mikkola, M.; Olsson, C.; Blomqvist, M.; Tiittanen, M.; Jaatinen, T.; Aitio, O.; Olonen, A.; Helin, J.; et al. The N-glycome of human embryonic stem cells. BMC Cell Biol. 2009, 10, 42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Deutsch, E.W.; Csordas, A.; Sun, Z.; Jarnuczak, A.; Perez-Riverol, Y.; Ternent, T.; Campbell, D.S.; Bernal-Llinares, M.; Okuda, S.; Kawano, S.; et al. The ProteomeXchange consortium in 2017: Supporting the cultural change in proteomics public data deposition. Nucleic Acids Res. 2017, 45, D1100–D1106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Perez-Riverol, Y.; Bai, J.; Bandla, C.; García-Seisdedos, D.; Hewapathirana, S.; Kamatchinathan, S.; Kundu, D.J.; Prakash, A.; Frericks-Zipper, A.; Eisenacher, M.; et al. The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2021, 50, D543–D552. [Google Scholar] [CrossRef] [PubMed]
  26. Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. Royal Statistical Soc. Ser. B Methodol. 1995, 57, 289–300. [Google Scholar] [CrossRef]
  27. Thiel, A.; Heinonen, M.; Kantonen, J.; Gylling, A.; Lahtinen, L.; Korhonen, M.; Kytölä, S.; Mecklin, J.-P.; Orpana, A.; Peltomäki, P.; et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch. 2013, 463, 613–621. [Google Scholar] [CrossRef]
  28. Ukkola, I.; Nummela, P.; Pasanen, A.; Kero, M.; Lepistö, A.; Kytölä, S.; Bützow, R.; Ristimäki, A. Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer. Virchows Arch. 2021, 479, 471–479. [Google Scholar] [CrossRef]
  29. Sethi, M.K.; Hancock, W.S.; Fanayan, S. Identifying N-Glycan Biomarkers in Colorectal Cancer by Mass Spectrometry. Accounts Chem. Res. 2016, 49, 2099–2106. [Google Scholar] [CrossRef]
  30. Zhang, D.; Xie, Q.; Wang, Q.; Wang, Y.; Miao, J.; Li, L.; Zhang, T.; Cao, X.; Li, Y. Mass spectrometry analysis reveals aberrant N-glycans in colorectal cancer tissues. Glycobiology 2019, 29, 372–384. [Google Scholar] [CrossRef]
  31. Boyaval, F.; van Zeijl, R.; Dalebout, H.; Holst, S.; van Pelt, G.W.; Fariña-Sarasqueta, A.; Mesker, W.E.; Tollenaar, R.; Morreau, H.; Wuhrer, M.; et al. N-Glycomic Signature of Stage II Colorectal Cancer and Its Association With the Tumor Microenvironment. Mol. Cell Proteom. 2021, 20, 100057. [Google Scholar] [CrossRef] [PubMed]
  32. Boyaval, F.; Dalebout, H.; Van Zeijl, R.; Wang, W.; Fariña-Sarasqueta, A.; Lageveen-Kammeijer, G.S.M.; Boonstra, J.J.; McDonnell, L.A.; Wuhrer, M.; Morreau, H.; et al. High-Mannose N-Glycans as Malignant Progression Markers in Early-Stage Colorectal Cancer. Cancers 2022, 14, 1552. [Google Scholar] [CrossRef]
  33. Coura, M.d.M.; Barbosa, E.A.; Brand, G.D.; Bloch, C.; de Sousa, J.B. Identification of Differential N-Glycan Compositions in the Serum and Tissue of Colon Cancer Patients by Mass Spectrometry. Biology 2021, 10, 343. [Google Scholar] [CrossRef]
  34. Sethi, M.K.; Kim, H.; Park, C.K.; Baker, M.S.; Paik, Y.-K.; Packer, N.H.; Hancock, W.S.; Fanayan, S.; Thaysen-Andersen, M. In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation. Glycobiology 2015, 25, 1064–1078. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Park, J.-J.; Lee, M. Increasing the α 2, 6 Sialylation of Glycoproteins May Contribute to Metastatic Spread and Therapeutic Resistance in Colorectal Cancer. Gut Liver 2013, 7, 629–641. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. de Freitas, J.C.M., Jr.; Morgado-Díaz, J.A. The role of N-glycans in colorectal cancer progression: Potential biomarkers and therapeutic applications. Oncotarget 2015, 7, 19395–19413. [Google Scholar] [CrossRef] [Green Version]
  37. Birgisson, H.; Edlund, K.; Wallin, U.; Påhlman, L.; Kultima, H.G.; Mayrhofer, M.; Micke, P.; Isaksson, A.; Botling, J.; Glimelius, B.; et al. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer 2015, 15, 125. [Google Scholar] [CrossRef] [Green Version]
  38. Tran, B.; Kopetz, S.; Tie, J.; Gibbs, P.; Jiang, Z.-Q.; Lieu, C.H.; Agarwal, A.; Maru, D.M.; Sieber, O.; Desai, J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011, 117, 4623–4632. [Google Scholar] [CrossRef] [Green Version]
  39. Tan, E.; Whiting, J.; Xie, H.; Imanirad, I.; Carballido, E.; Felder, S.; Frakes, J.; Mo, Q.; Walko, C.; Permuth, J.B.; et al. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer. Oncologist 2022, 27, 191–197. [Google Scholar] [CrossRef]
  40. Dennis, J.W.; Laferté, S.; Waghorne, C.; Breitman, M.L.; Kerbel, R.S. β1-6 Branching of Asn-Linked Oligosaccharides Is Directly Associated with Metastasis. Science 1987, 236, 582–585. [Google Scholar] [CrossRef]
  41. Murata, K.; Miyoshi, E.; Kameyama, M.; Ishikawa, O.; Kabuto, T.; Sasaki, Y.; Hiratsuka, M.; Ohigashi, H.; Ishiguro, S.; Ito, S.; et al. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin. Cancer Res. 2000, 6, 1772–1777. [Google Scholar] [PubMed]
  42. Kim, Y.-S.; Hwang, S.Y.; Kang, H.-Y.; Sohn, H.; Oh, S.; Kim, J.-Y.; Yoo, J.S.; Kim, Y.H.; Kim, C.-H.; Jeon, J.-H.; et al. Functional Proteomics Study Reveals that N-Acetylglucosaminyltransferase V Reinforces the Invasive/Metastatic Potential of Colon Cancer through Aberrant Glycosylation on Tissue Inhibitor of Metalloproteinase-1. Mol. Cell Proteom. 2008, 7, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Carvalho, S.; Reis, C.; Pinho, S.S. Cadherins Glycans in Cancer: Sweet Players in a Bitter Process. Trends Cancer 2016, 2, 519–531. [Google Scholar] [CrossRef] [PubMed]
  44. Brockhausen, I.; Kuhns, W. Role and Metabolism of Glycoconjugate Sulfation. Trends Glycosci. Glycotechnol. 1997, 9, 379–398. [Google Scholar] [CrossRef] [Green Version]
  45. Chandrasekaran, E.V.; Xue, J.; Piskorz, C.; Locke, R.D.; Tóth, K.; Slocum, H.K.; Matta, K.L. Potential tumor markers for human gastric cancer: An elevation of glycan: Sulfotransferases and a concomitant loss of α1,2-fucosyltransferase activities. J. Cancer Res. Clin. Oncol. 2007, 133, 599–611. [Google Scholar] [CrossRef]
  46. Capon, C.; Wieruszeski, J.-M.; Lemoine, J.; Byrd, J.C.; Leffler, H.; Kim, Y.S. Sulfated Lewis X Determinants as a Major Structural Motif in Glycans from LS174T-HM7 Human Colon Carcinoma Mucin. J. Biol. Chem. 1997, 272, 31957–31968. [Google Scholar] [CrossRef] [Green Version]
  47. Horlacher, T.; Oberli, M.A.; Werz, D.B.; Kröck, L.; Bufali, S.; Mishra, R.; Sobek, J.; Simons, K.; Hirashima, M.; Niki, T.; et al. Determination of Carbohydrate-Binding Preferences of Human Galectins with Carbohydrate Microarrays. Chembiochem 2010, 11, 1563–1573. [Google Scholar] [CrossRef]
  48. Hittelet, A.; Legendre, H.; Nagy, N.; Bronckart, Y.; Pector, J.-C.; Salmon, I.; Yeaton, P.; Gabius, H.-J.; Kiss, R.; Camby, I. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int. J. Cancer 2002, 103, 370–379. [Google Scholar] [CrossRef]
  49. Peng, K.-Y.; Jiang, S.-S.; Lee, Y.-W.; Tsai, F.-Y.; Chang, C.-C.; Chen, L.-T.; Yen, B.L. Stromal Galectin-1 Promotes Colorectal Cancer Cancer-Initiating Cell Features and Disease Dissemination Through SOX9 and β-Catenin: Development of Niche-Based Biomarkers. Front. Oncol. 2021, 11, 716055. [Google Scholar] [CrossRef]
  50. Holst, S.; Deuss, A.J.; van Pelt, G.W.; van Vliet, S.J.; Garcia-Vallejo, J.J.; Koeleman, C.A.; Deelder, A.M.; Mesker, W.E.; Tollenaar, R.A.; Rombouts, Y.; et al. N-glycosylation Profiling of Colorectal Cancer Cell Lines Reveals Association of Fucosylation with Differentiation and Caudal Type Homebox 1 (CDX1)/Villin mRNA Expression. Mol. Cell Proteom. 2016, 15, 124–140. [Google Scholar] [CrossRef] [Green Version]
  51. Holst, S.; Wilding, J.L.; Koprowska, K.; Rombouts, Y.; Wuhrer, M. N-Glycomic and Transcriptomic Changes Associated with CDX1 mRNA Expression in Colorectal Cancer Cell Lines. Cells 2019, 8, 273. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Guo, R.-J.; Suh, E.R.; Lynch, J.P. The role of Cdx proteins in intestinal development and cancer. Cancer Biol. Ther. 2004, 3, 593–601. [Google Scholar] [CrossRef] [PubMed]
  53. Sethi, M.K.; Thaysen-Andersen, M.; Smith, J.T.; Baker, M.S.; Packer, N.H.; Hancock, W.S.; Fanayan, S. Comparative N-Glycan Profiling of Colorectal Cancer Cell Lines Reveals Unique Bisecting GlcNAc and α-2,3-Linked Sialic Acid Determinants Are Associated with Membrane Proteins of the More Metastatic/Aggressive Cell Lines. J. Proteome Res. 2013, 13, 277–288. [Google Scholar] [CrossRef] [PubMed]
  54. Raffaghello, L.; Dazzi, F. Classification and biology of tumour associated stromal cells. Immunol. Lett. 2015, 168, 175–182. [Google Scholar] [CrossRef] [PubMed]
  55. Berois, N.; Pittini, A.; Osinaga, E. Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. Cancers 2022, 14, 645. [Google Scholar] [CrossRef]
Cancers 15 03571 g001 550
Figure 1. Major types and features of N-glycans. Representative N-glycan structures are depicted by green circles (D-mannose), blue squares (N-acetyl-D-glucosamine), yellow squares (N-acetyl-D-galactosamine), red triangles (L-fucose), yellow circles (D-galactose), purple diamonds (N-acetylneuraminic acid, sialic acid), and open circles with an “S” (sulfate or phosphate ester). The major N-glycan structural classes are shown below the schematic structures. Additional N-glycan structural features are indicated in boxes. H = hexose; N = N-acetylhexosamine = HexNAc; F = deoxyhexose (fucose), S = sialic acid; P = acid ester (sulfate/phosphate).
Figure 1. Major types and features of N-glycans. Representative N-glycan structures are depicted by green circles (D-mannose), blue squares (N-acetyl-D-glucosamine), yellow squares (N-acetyl-D-galactosamine), red triangles (L-fucose), yellow circles (D-galactose), purple diamonds (N-acetylneuraminic acid, sialic acid), and open circles with an “S” (sulfate or phosphate ester). The major N-glycan structural classes are shown below the schematic structures. Additional N-glycan structural features are indicated in boxes. H = hexose; N = N-acetylhexosamine = HexNAc; F = deoxyhexose (fucose), S = sialic acid; P = acid ester (sulfate/phosphate).
Cancers 15 03571 g001
Cancers 15 03571 g002 550
Figure 2. Change in the relative abundances of acidic N-glycan classes when comparing MSI BRAFV600E wild-type and mutant CRC samples within the stage. The x-axis shows the percentage increase or decrease in the relative abundances of the significantly different acidic N-glycan classes between the BRAF wild-type and mutant samples within stage II (lavender) and stage IV (purple). Representative N-glycan structures are depicted by green circles (D-mannose), blue squares (N-acetyl-D-glucosamine), yellow squares (N-acetyl-D-galactosamine), red triangles (L-fucose), yellow circles (D-galactose), purple diamonds (N-acetylneuraminic acid, sialic acid), and open circles with an “S” (sulfate or phosphate ester). * NS = not significant (in stage IV).
Figure 2. Change in the relative abundances of acidic N-glycan classes when comparing MSI BRAFV600E wild-type and mutant CRC samples within the stage. The x-axis shows the percentage increase or decrease in the relative abundances of the significantly different acidic N-glycan classes between the BRAF wild-type and mutant samples within stage II (lavender) and stage IV (purple). Representative N-glycan structures are depicted by green circles (D-mannose), blue squares (N-acetyl-D-glucosamine), yellow squares (N-acetyl-D-galactosamine), red triangles (L-fucose), yellow circles (D-galactose), purple diamonds (N-acetylneuraminic acid, sialic acid), and open circles with an “S” (sulfate or phosphate ester). * NS = not significant (in stage IV).
Cancers 15 03571 g002
Table
Table 1. Seven different study groups analyzed for neutral and acidic N-glycans.
Table 1. Seven different study groups analyzed for neutral and acidic N-glycans.
NumberStudy Groupn
1Non-neoplastic controls vs. all MSI CRC 4 pools vs. 40
2CRC Stage II BRAFwt MSI vs. MSS10 vs. 9
3MSI CRC Stage II BRAFwt vs. BRAFmut10 vs. 10
4MSI CRC Stage II vs. IV20 vs. 20
5MSI CRC BRAFwt Stage II vs. IV10 vs. 10
6MSI CRC BRAFmut Stage II vs. IV10 vs. 10
7MSI CRC Stage IV BRAFwt vs. BRAFmut10 vs. 10
Table
Table 2. Characteristics of the CRC subgroups used in the study.
Table 2. Characteristics of the CRC subgroups used in the study.
SubgroupSubgroup
All MSI CRC (n = 40)Age 73 (51–89)MSS CRC Stage II BRAFwt (n = 9)Age 59 (52–77)
Sex♀ 28 (70%) Sex♀ 4 (44%)
♂ 12 (30%) ♂ 5 (56%)
Tumor siteR 35 (88%) Tumor siteR 4 (44%)
L 5 (12%) L 5 (56%)
GradeLG 23 (58%) GradeLG 7 (78%)
HG 17 (42%) HG 2 (22%)
pTT2 1 (2%) pTT2 0 (0%)
T3 25 (63%) T3 8 (89%)
T4 14 (35%) T4 1 (11%)
pNN0 26 (65%) pNN0 9 (100%)
N1 3 (7%) N1 0 (0%)
N2 11 (28%) N2 0 (0%)
MM0 20 (50%) MM0 9 (100%)
M1 20 (50%) M1 0 (0%)
MSI CRC Stage II BRAFwt (n = 10)Age 72 (51–78)MSI CRC Stage II BRAFmut (n = 10)Age 71 (58–82)
Sex♀ 7 (70%) Sex♀ 7 (70%)
♂ 3 (30%) ♂ 3 (30%)
Tumor siteR 8 (80%) Tumor siteR 8 (80%)
L 2 (20%) L 2 (20%)
GradeLG 6 (60%) GradeLG 6 (60%)
HG 4 (40%) HG 4 (40%)
pTT3 7 (70%) pTT3 8 (80%)
T4 3 (30%) T4 2 (20%)
pNN0 10 (100%) pNN0 10 (100%)
MM0 10 (100%) MM0 10 (100%)
MSI CRC Stage IV BRAFwt (n = 10)Age 74 (54–86) MSI CRC Stage IV BRAFmut (n = 10)Age 75 (63–89)
Sex♀ 7 (70%) Sex♀ 7 (70%)
♂ 3 (30%) ♂ 3 (30%)
Tumor siteR 9 (90%) Tumor siteR 10 (100%)
L 1 (10%) L 0 (0%)
GradeLG 4 (40%) GradeLG 7 (70%)
HG 6 (60%) HG 3 (30%)
pTT2 1 (10%) pTT2 0 (0%)
T3 3 (30%) T3 7 (79%)
T4 6 (60%) T4 3 (30%)
pNN0 1 (10%) pNN0 5 (50%)
N1 3 (30%) N1 0 (0%)
N2 6 (60%) N2 5 (50%)
MM1a 4 (40%) MM1a 5 (50%)
M1b 2 (20%) M1b 4 (40%)
M1c 4 (40%) M1c 1 (10%)
CRC, colorectal cancer; HG, high-grade; L, left; LG, low-grade; M, metastases; mut, mutated; N, nodes; MSI, microsatellite instability; MSS, microsatellite stable; R, right; T, tumor; wt, wild-type.
Table
Table 3. Relative abundances of significantly different neutral and acidic N-glycan classes between the controls (n = 4 pools) and the MSI CRC samples (n = 40).
Table 3. Relative abundances of significantly different neutral and acidic N-glycan classes between the controls (n = 4 pools) and the MSI CRC samples (n = 40).
CtrlsMSI CRCFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
NEUTRAL
5 HexNAc15.31.38.30.70.50.007
High-mannose type40.22.633.01.20.80.039
Pauci-mannose type 15.51.324.11.21.60.045
Biantennary-size in complex-type25.71.736.81.61.40.044
Monoantennary in hybrid-type38.01.845.21.01.20.028
Fucosylation in pauci-mannose type 51.71.371.81.81.40.011
Fucosylation in hybrid-type52.21.265.32.01.30.014
Terminal HexNAc 17.71.313.11.00.70.039
ACIDIC
Fucosylation in complex-type71.91.957.82.00.80.028
a Benjamini–Hochberg; CRC, colorectal cancer; HexNAc, N-acetylhexosamine; MSI, microsatellite instability; SEM, standard error of mean.
Table
Table 4. Relative abundances of significantly different neutral N-glycan classes between MSS BRAFwt stage II and MSI BRAFwt stage II samples.
Table 4. Relative abundances of significantly different neutral N-glycan classes between MSS BRAFwt stage II and MSI BRAFwt stage II samples.
MSS St II BRAFwtMSI St II BRAFwtFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
2 HexNAc 74.13.054.85.00.70.005
3 HexNAc6.40.44.80.30.80.016
4 HexNAc 9.51.229.14.73.10.001
5 HexNAc4.61.08.51.41.80.030
High-mannose type 53.82.431.93.20.60.001
Complex type16.82.540.44.92.40.002
Biantennary-size in complex-type27.54.141.13.41.50.025
Monoantennary in hybrid-type29.34.243.12.81.50.013
Fucosylation25.62.350.55.12.00.006
Fucosylation in pauci-mannose type 43.03.069.95.51.60.005
Terminal HexNAc in hybrid-type 1.51.03.10.32.10.040
Terminal HexNAc in complex-type41.75.127.92.80.70.030
a Benjamini–Hochberg HexNAc, N-acetylhexosamine; MSI, microsatellite instability; MSS, microsatellite stabile; mut, mutated; SEM, standard error of mean; St, stage; wt, wild-type.
Table
Table 5. Relative abundances of significantly different acidic N-glycan classes between MSS BRAFwt stage II and MSI BRAFwt stage II samples.
Table 5. Relative abundances of significantly different acidic N-glycan classes between MSS BRAFwt stage II and MSI BRAFwt stage II samples.
MSS St II BRAFwtMSI St II BRAFwtFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
3 HexNAc 10.01.31.90.50.20.002
4 HexNAc 41.94.374.63.61.80.002
5 HexNAc19.81.013.80.80.70.001
6 HexNAc 14.91.95.41.50.40.007
7 HexNAc or larger 13.53.44.31.60.30.030
Complex-type 90.11.398.10.51.10.002
Biantennary-size in complex-type42.94.775.53.51.80.002
Fucosylation 75.62.956.34.30.70.017
Fucosylation in complex-type 76.83.055.84.20.70.013
Complex fucosylation35.05.212.62.60.40.011
Complex fucosylation in hybrid-type16.15.21.51.50.10.011
Complex fucosylation in complex-type36.95.312.82.70.30.011
Terminal HexNAc20.95.42.00.80.10.004
Terminal HexNAc in complex-type23.36.02.00.80.10.003
Terminal HexNAc (bisecting-size) in complex-type14.02.85.32.00.40.017
Sulfate/phosphate in hybrid type34.78.69.46.30.30.019
a Benjamini–Hochberg HexNAc, N-acetylhexosamine; MSI, microsatellite instability; MSS, microsatellite stabile; mut, mutated; SEM, standard error of mean; St, stage; wt, wild-type.
Table
Table 6. Relative abundances of significantly different acidic N-glycan classes between MSI CRC subgroups.
Table 6. Relative abundances of significantly different acidic N-glycan classes between MSI CRC subgroups.
MSI St II BRAFwtMSI St II BRAFmutFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
4 HexNAc74.63.693.21.21.20.002
5 HexNAc 13.80.84.70.60.30.001
6 HexNAc 5.41.50.60.20.10.007
7 HexNAc or larger4.31.60.00.0None in BRAFmut0.001
Large N-glycans21.92.94.70.70.20.001
Biantennary-size in complex-type75.53.594.40.71.30.001
Terminal HexNAc2.00.80.70.70.40.023
Terminal HexNAc in complex-type 2.00.80.70.70.40.023
Terminal HexNAc (bisecting-size) in complex-type5.32.00.40.20.10.005
Sialylated88.14.6100.00.01.10.008
Sialylated complex-type88.14.6100.00.01.10.008
Sulfate or phosphate 12.04.60.00.0None in BRAFmut0.008
Sulfate/phosphate in complex-type12.04.60.00.0None in BRAFmut0.008
MSI St IIMSI St IVFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
Biantennary-size in complex-type84.92.878.02.90.90.038
MSI St II BRAFwtMSI St IV BRAFwtFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
5 HexNAc 13.80.810.20.40.70.009
7 HexNAc or larger4.31.60.40.20.10.030
Large N-glycans 21.92.912.30.70.60.020
Biantennary-size in complex-type75.53.586.00.81.10.032
MSI St II BRAFmutMSI St IV BRAFmutFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
4 HexNAc93.21.269.74.30.70.001
5 HexNAc4.70.616.51.63.50.001
6 HexNAc 0.60.27.71.912.80.002
7 HexNAc or larger0.00.04.51.6None in St II0.001
Large N-glycans4.70.723.13.14.90.001
Biantennary-size in complex-type94.40.769.94.50.70.001
Terminal HexNAc0.70.76.11.88.70.006
Terminal HexNAc in complex-type 0.70.76.21.88.90.006
Terminal HexNAc (bisecting-size) in complex-type0.40.27.93.419.80.001
Sialylated100.00.089.83.40.90.004
Sialylated complex-type 100.00.089.93.40.90.004
Sulfate/phosphate0.00.010.73.4None in St II0.002
Sulfate/phosphate in complex-type 0.00.010.63.4None in St II0.002
MSI St IV BRAFwtMSI St IV BRAFmutFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
4 HexNAc85.20.869.74.30.80.002
5 HexNAc10.20.416.51.61.60.005
6 HexNAc2.00.67.71.93.90.005
7 HexNAc or larger0.40.24.51.611.30.011
Large N-glycans 12.30.723.13.11.90.001
Biantennary-size in complex-type86.00.869.94.50.80.001
Terminal HexNAc 0.60.26.11.810.20.019
Terminal HexNAc in complex-type 0.60.26.21.810.30.019
Terminal HexNAc (bisecting-size) in complex-type1.80.57.93.44.40.007
Sulfate/phosphate1.81.710.73.45.90.019
Sulfate/phosphate in complex-type 1.81.710.63.45.90.019
a Benjamini–Hochberg HexNAc, N-acetylhexosamine; MSI, microsatellite instability; mut, mutated; SEM, standard error of mean; St, stage; wt, wild-type.
Table
Table 7. Relative abundances of significantly different neutral N-glycan classes between MSI subgroups.
Table 7. Relative abundances of significantly different neutral N-glycan classes between MSI subgroups.
MSI St IIMSI St IVFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
3 HexNAc5.30.36.70.41.30.017
Fucosylation in high-mannose type0.90.11.10.11.20.027
MSI St II BRAFmutMSI St IV BRAFmutFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
Monoantennary in hybrid-type49.51.141.61.30.80.008
MSI St IV BRAFwtMSI St IV BRAFmutFold Changep-Adjusted a
Average (%)SEMAverage (%)SEM
Fucosylation in pauci-mannose type77.31.266.03.90.90.024
a Benjamini–Hochberg HexNAc, N-acetylhexosamine; MSI, microsatellite instability; mut, mutated; SEM, standard error of mean; St, stage; wt, wild-type.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ukkola, I.; Nummela, P.; Heiskanen, A.; Holm, M.; Zafar, S.; Kero, M.; Haglund, C.; Satomaa, T.; Kytölä, S.; Ristimäki, A. N-Glycomic Profiling of Microsatellite Unstable Colorectal Cancer. Cancers 2023, 15, 3571. https://doi.org/10.3390/cancers15143571

AMA Style

Ukkola I, Nummela P, Heiskanen A, Holm M, Zafar S, Kero M, Haglund C, Satomaa T, Kytölä S, Ristimäki A. N-Glycomic Profiling of Microsatellite Unstable Colorectal Cancer. Cancers. 2023; 15(14):3571. https://doi.org/10.3390/cancers15143571

Chicago/Turabian Style

Ukkola, Iiris, Pirjo Nummela, Annamari Heiskanen, Matilda Holm, Sadia Zafar, Mia Kero, Caj Haglund, Tero Satomaa, Soili Kytölä, and Ari Ristimäki. 2023. "N-Glycomic Profiling of Microsatellite Unstable Colorectal Cancer" Cancers 15, no. 14: 3571. https://doi.org/10.3390/cancers15143571

APA Style

Ukkola, I., Nummela, P., Heiskanen, A., Holm, M., Zafar, S., Kero, M., Haglund, C., Satomaa, T., Kytölä, S., & Ristimäki, A. (2023). N-Glycomic Profiling of Microsatellite Unstable Colorectal Cancer. Cancers, 15(14), 3571. https://doi.org/10.3390/cancers15143571

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop